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A Paradigm Shift?*Magdi H. Yacoub, MD, PHDSEE PAGE 892T he heart failure epidemic continues largelyunabated, with more than 26 million peopleaffected worldwide (1,2). Despite “optimal
medical treatment,” severe forms of the disease carry
a very poor prognosis (3–6), with cardiac transplanta-
tion being the only long-term solution. Due to the
great shortage of donor organs, increasing numbers
of patients require an alternative therapy. Left ven-
tricular assist devices (LVADs) have been used exten-
sively as a bridge-to-transplantation or destination
therapy, with more than 25,000 devices implanted
worldwide and more than 2,000 implantations per
year in the United States alone (7). After LVAD implan-
tation, a signiﬁcant minority of patients display signs
of heart failure reversal, with structural and functional
changes in the myocardium, termed reverse remodel-
ing. The incidence and extent of reverse remodeling
vary in different series. This could be due to several
factors, including the occasional use of combination
therapy, which aims to maximize recovery to enable
explantation of the device (8). The success of these
strategies depends on a thorough understanding of
the exact mechanisms of reverse remodeling. Unfortu-
nately, this has not yet been achieved, even with a
large number of observational studies showing
cellular and molecular changes in different myocar-
dial components, both clinically and in experimental*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.models of unloading (9,10). Whether these changes
are the cause or the effect of reverse remodeling
remains largely unknown. Molecular and cellular
changes, which involve many myocardial cells and
systems, have been postulated to represent compo-
nents of a complex network with decision and hub
nodes (11). Analysis of such a network requires com-
plete data related to the nodes and application of
system biology tools. In this issue of the Journal,
the report by Canseco et al. (12) might representa paradigm shift, deﬁned by Thomas Kuhn (13) as
“a change in the basic assumptions, or paradigms,
within the ruling theory of science.” The authors pre-
sent evidence of an increased rate of myocardial cell
division in paired myocardial samples after different
periods of unloading using LVADs, documented by
direct and indirect methods. This was accompanied
by decreased numbers of mitochondria and oxidative
stress, with a resultant decrease in the DNA damage
response. Recent work by the same authors suggested
that similar changes in neonatal hearts were respon-
sible for the loss of the capacity of neonatal mouse
cardiomyocytes to divide (14). This sharply contrasts
with the zebraﬁsh and salamander, in which cardio-
myocytes retain their capacity to divide into adult
life (Figure 1). This difference is thought to be the
main cause of heart failure development after
myocardial infarction and other conditions causing
myocardial cell damage.
CAPACITY OF ADULT CARDIOMYOCYTES
TO DIVIDE
Several studies using different techniques have docu-
mented that adult human and mouse cardiomyocytes
FIGURE 1 Effects of Inhibiting ROS Release by Mitochondria
The new proposed mechanism for inducing myocardial cell division (12,14). ROS ¼ reactive oxygen species.
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902retain the capacity to divide, albeit very slowly
(Table 1) (15). This was investigated by Bergmann et al.
(16) by making use of accidental labeling of adult hu-
man cardiomyocytes by 14C from the atomic bomb
tests. They showed that by 20 years of age, the rate of
division was w1%, decreasing to 0.3% by 75 years of
age. Questions of whether and how this rate can be
accelerated in humans and how to translate this into
clinically useful strategies remain open.
MYOCARDIAL UNLOADING AND
CARDIOMYOCYTES
The report by Canseco et al. (12) is the ﬁrst to show
a link between myocardial unloading and cell divi-
sion in humans. Cardiomyocytes contain mechanore-
ceptors (17); however, their function, particularly in
relation to myocardial cell division, remains largely
unknown. Canseco et al. (12) implicate metabolic
pathways involving mitochondria and oxidative
stress.THE MANY FACES OF MITOCHONDRIA
The prevailing theory of the origin, evolution, and
functions of mitochondria is that they represent
bacterial DNA and proteins that were devoured by
karyocytes during evolution (18). Genealogical evi-
dence suggests that all living humans share mito-
chondrial DNA from a single female originating in
Africa, commonly referred to as the matrilineal most
common recent ancestor or “mitochondrial Eve”
(19,20). This seriously challenges the prevailing
multiregional theory of human evolution (21).
One of the most important functions of mitochon-
dria is to act as a powerhouse to supply energy
essential for appropriate function of cardiomyocytes.
The ﬁndings of Canseco et al. (12) suggest that this
does not come without a price because an increased
number of mitochondria results in increased oxida-
tive stress, which is known to have deleterious
effects, including interfering with myocyte division.
It appears, therefore, that the relationship between
TABLE 1 Annual Myocyte Turnover in Adult Human and
Mouse Hearts
First Author (Ref. #) Method
Annual
Turnover, %
Adult human heart
Bergmann et al. (16) 14C 0.45–1.0
Kajsutra et al. (22) 14C 7–19
Kajsutra et al. (23) Ki67, H3P, Aurora B 7–40
Kalsutra et al. (24) IdU 7.3–256
Mollova et al. (25) H3P 0.04–1.9
Adult mouse heart
Soonpaa et al. (26,27) 3H-thymidine 1.1
Walsh et al. (28) BrdU 0
Senyo et al. (29) N-thymidine 0.74–4.4
Malliaras et al. (30) BrdU 1.3–4.0
Hosoda et al. (31) Viral tagging 25–50
Values are %, or median, unless otherwise noted. Modiﬁed with permission from
Malliaras et al. (15).
BrdU¼ bromodeoxyuridine; H3P¼ phosphorylated histone H3; IdU¼ idoxuridine.
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903mitochondria and cardiomyocytes is complex and
not necessarily symbiotic.
Taken together, the ﬁndings of Canseco et al. (12)
are novel and extremely interesting. If validated
in larger multicenter trials using clinically re-
levant biomarkers and endpoints, they could have a
major impact on optimizing the management of
patients with LVADs and, importantly, identifying
new therapeutic targets for patients with advanced
heart failure.
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